Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug–drug interactions

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Xenobiotica; the fate of foreign compounds in biological systems

• Publication date

  2009-03-01

• Fields of study

  Medicine, Chemistry, Environmental Science

• Identifiers
  DOI 10.1080/00498250802657718PMID 19280525
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Organic acid concentrations and digesta movement in the gastrointestinal tract of the bushbaby (Galago crassicaudatus) and Vervet monkey (Cercopithecidae pygerythrus)

  2009cited by this paper
• Exploration of the African Green Monkey as a Preclinical Pharmacokinetic Model: Intravenous Pharmacokinetic Parameters

  2008cited by this paper
• Interspecies Prediction of Human Drug Clearance Based on Scaling Data from One or Two Animal Species

  2007cited by this paper
• In Vivo and in Vitro Characterization of Chlorzoxazone Metabolism and Hepatic CYP2E1 Levels in African Green Monkeys: Induction by Chronic Nicotine Treatment

  2006cited by this paper
• EXTRAPOLATION OF PRECLINICAL PHARMACOKINETICS AND MOLECULAR FEATURE ANALYSIS OF “DISCOVERY-LIKE” MOLECULES TO PREDICT HUMAN PHARMACOKINETICS

  2006cited by this paper
• Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys

  2005cited by this paper
• Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human

  2005cited by this paper
• A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance.

  2004cited by this paper
• Development of an in vivo preclinical screen model to estimate absorption and first-pass hepatic extraction of xenobiotics. II. Use of ketoconazole to identify P-glycoprotein/CYP3A-limited bioavailability in the monkey.

  2004cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time.

  2004cited by this paper
• Development of an in vivo preclinical screen model to estimate absorption and bioavailability of xenobiotics.

  2001cited by this paper
• Effects of chair‐restraint on gastrointestinal transit time and colonic fermentation in male rhesus monkey (Macaca mulatta)

  1997cited by this paper
• Nonlinear Pharmacokinetics

  1991cited by this paper
• Distribution and metabolism of prednisone in mice, dogs, and monkeys.

  1977cited by this paper

• Ocular examination findings and selected ophthalmic diagnostic tests in African green monkeys (Chlorocebus aethiops sabaeus).

  2023cites this paper
• Application of an Inter-Species Extrapolation Method for the Prediction of Drug Interactions between Propolis and Duloxetine in Humans

  2020cites this paper
• Novel pre-clinical methodologies for pharmacokinetic drug–drug interaction studies: spotlight on “humanized” animal models

  2014cites this paper
• The Use of the African Green Monkey as a Preclinical Model for Ocular Pharmacokinetic Studies

  2012cites this paper
• The effect of Pheroid™ technology on the bioavailability of quinoline–based anti–malarial compounds in primates

  2012cites this paper
• Delayed match-to-sample performance in African green monkeys (Chlorocebus aethiops sabaeus): effects of benzodiazepine, cholinergic, and anticholinergic drugs

  2011cites this paper
• Pharmacokinetics and anti-inflammatory pharmacodynamics of prednisolone in cynomolgus monkey

  2009cites this paper